Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Hold” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received a consensus recommendation of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

A number of equities analysts recently weighed in on the company. Truist Financial raised their price objective on Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, December 11th. HC Wainwright increased their target price on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Cantor Fitzgerald raised their price target on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Citigroup reaffirmed an “underperform” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th.

Fulcrum Therapeutics Stock Up 1.7%

Shares of NASDAQ FULC opened at $12.00 on Thursday. The stock’s 50-day simple moving average is $10.28 and its two-hundred day simple moving average is $8.41. The firm has a market capitalization of $649.15 million, a P/E ratio of -10.17 and a beta of 3.17. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, research analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the completion of the transaction, the director directly owned 484,864 shares in the company, valued at $5,348,049.92. The trade was a 3.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in FULC. Acadian Asset Management LLC grew its holdings in shares of Fulcrum Therapeutics by 865.0% in the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after purchasing an additional 308,854 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Fulcrum Therapeutics in the first quarter worth about $425,000. Exome Asset Management LLC boosted its holdings in Fulcrum Therapeutics by 143.0% during the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after acquiring an additional 405,538 shares during the period. Strs Ohio purchased a new stake in shares of Fulcrum Therapeutics during the first quarter valued at $263,000. Finally, Bailard Inc. bought a new position in Fulcrum Therapeutics in the 2nd quarter worth about $185,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.